| Document |
Document Title |
|
WO/2024/054682A3 |
Provided herein are heparin oligomers (e.g., heparin oligomers of Formula (I)), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs ther...
|
|
WO/2024/102718A1 |
The present invention relates to a method of treating insomnia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
|
|
WO/2024/099391A1 |
Disclosed herein are a lipid-charged molecule conjugate, an inhalable lipid nanoparticle, a preparation method therefor, and use thereof. The lipid-charged molecule conjugate of the present invention comprises a lipid unit and a charged ...
|
|
WO/2024/100051A1 |
The invention relates to compounds for use in the treatment of liver failure.
|
|
WO/2024/098890A1 |
A pyridone compound and a preparation method therefor, a pharmaceutical composition and a use. The structure of the pyridone compound is as shown in formula (I), and the pyridone compound comprises an isomer, a pharmaceutically acceptabl...
|
|
WO/2024/102219A1 |
A method of treating acne, of treating UV or radiation induced injury, of reducing the appearance of scars, and/or of treating mucositis, including topically applying a composition including CAPE to a human or other mammal in need thereo...
|
|
WO/2024/102177A1 |
Disclosed herein are methods of treating brain cancer in a subject, such as glioblastoma, comprising administering inhibitors of synaptic signaling to the subject.
|
|
WO/2024/100203A1 |
Methods of cancer treatment comprise administration of a modified natural killer (NK) cell in combination with an immunomodulatory drug. Also described are compositions comprising a combination of a modified NK cell and an immunomodulato...
|
|
WO/2024/100421A1 |
The invention relates to therapeutic uses of SARM1 agents (e.g. molecule that causes neurodegeneration and/or neuronal dysfunction in a SARM1 -dependent manner) such as Vacor, metabolites, analogs, and derivatives thereof for treating an...
|
|
WO/2024/102342A1 |
The present invention relates to a process of removing free-unlabeled radionuclides from a radiopharmaceutical prior to administering the radiopharmaceutical to the patient using size-exclusion or ion-exchange mechanisms.
|
|
WO/2024/101918A1 |
The present invention relates to a lipo-hydroxamic acid derivative and a pharmaceutical use thereof, the derivative being usefully employable as a composition for prevention, treatment, or reduction of eye disease by having been confirme...
|
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/100212A1 |
The application relates to the crystalline Form 1S of Asciminib hydrochloride and processes for the preparation thereof. Also described are solvates of Asciminib with 2-butanol, isobutanol, tert- butanol, 2-methyl tetra hydrofuran and cy...
|
|
WO/2024/102078A1 |
This invention provides compounds according to formula (I): wherein A and Za are as defined in the specification. The compounds of formula (I) find use as heterobifunctional linkers. The present invention also provides compounds of formu...
|
|
WO/2024/102706A1 |
Provided herein are methods of treating, preventing, managing, and/or ameliorating androgen receptor mediated diseases with a combination of 3-((3- aminophenyl)amino)piperidine-2, 6-dione compounds and a second agent.
|
|
WO/2024/099336A1 |
The disclosure relates to thiadiazolyl derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
|
|
WO/2024/099269A1 |
Provided are following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodrug ...
|
|
WO/2024/102659A1 |
The disclosure provides engineered nucleotide sequences, vectors, and pharmaceutical compositions that can be used in methods for treating a disease or disorder with an associated haploinsufficiency and/or cancer.
|
|
WO/2024/102999A2 |
Disclosed herein are small molecules that effectively block the interaction of SARS-CoV-2 Spike protein with ACE2. Also disclosed are methods for treating viral infections that involve entry via endocytic pathways. In one aspect, the sma...
|
|
WO/2024/099226A1 |
The present invention relates to a biphenyl heteroaryl-containing dihydropteridinone derivative represented by general formula Ⅰ, and an optical isomer, pharmaceutically acceptable salt, solvate or prodrug thereof, a preparation method...
|
|
WO/2024/102952A1 |
A compound of formula I: Each variable is defined herein. Also disclosed are a pharmaceutical composition containing a compound of formula I, a method of treating cancer using such a compound, and a method of inhibiting SOS1 with the com...
|
|
WO/2024/101551A1 |
Disclosed is a thermosensitive hydrogel composition for the treatment, amelioration and prevention of periodontitis and gingivitis, comprising: bakuchiol; and poloxamer as active ingredients. According to the present invention, it is eas...
|
|
WO/2024/102976A1 |
Disclosures herein are directed to methods and compositions for predicting high- and low-risk for liver fibrosis progression in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease pat...
|
|
WO/2024/098894A1 |
Provided are a tumor-targeted imaging nano assembly, a preparation method therefor, and use thereof. The nano assembly comprises an active targeting unit, an imaging signal unit, and metal ions. The active targeting unit is coordinated w...
|
|
WO/2024/099404A1 |
The present application relates to a nitrogen-containing spirocyclic compound, a pharmaceutical composition and a use thereof. The nitrogen-containing spirocyclic compound has the structural formula represented by formula (I). The compou...
|
|
WO/2024/098967A1 |
The present invention provides use of an N-terminus kinase inhibitor SU3327 of C-JUN in preparing a drug for enhancing anti-bacterial-infection efficacy of polymyxin and use of a composition of the SU3327 and the polymyxin in preparing a...
|
|
WO/2024/098273A1 |
An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...
|
|
WO/2024/099996A1 |
The invention relates to a novel compound having the formula 6-[[(3R)-1-Ethyl-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-
4-methyl-1,2,4-triazin-5-one or 6-[[(3R)-1-ethyl-3-piperidyl]amino]-3-(2-hydroxy-3-bicyclo[4
.2.0]octa-1,3,5-trieny...
|
|
WO/2024/102672A2 |
The present disclosure provides methods for ameliorating or treating a neurological condition or disease in a subject in need of treatment thereof by administering to the subject a therapeutically effective amount of a composition compri...
|
|
WO/2024/100656A1 |
The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidat...
|
|
WO/2024/099520A1 |
The invention relates to 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. Here, a compound of general formula (I) is provided, where X is selected from the group consisting of a group of general formula (G1), a group of general fo...
|
|
WO/2024/101764A1 |
The present invention relates to: an isoindolinone derivative compound having a glutarimide mother nucleus in which quinoline is substituted; and application thereof, and, more specifically, to an isoindolinone derivative compound having...
|
|
WO/2024/101937A1 |
The present invention relates to a formulation capable of inhibiting the early release of a specific PRS inhibitor and has the effect of preventing the side effects of nausea or vomiting, which may occur when too much of an active ingred...
|
|
WO/2024/102833A2 |
A composition that includes a micro-RNA mimic containing one or more adenine bases in which at least one adenine base is replaced by 6-mercaptopurine. Also provided is a method for killing a cancer cell by contacting it with a compositio...
|
|
WO/2024/099435A1 |
The present invention provides a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. As a TEAD inhibitor, the compound can significantly inhibi...
|
|
WO/2024/073282A3 |
Disclosed herein are amino bicyclic nitrogen heterocyclic ring system compounds which inhibit nuclear receptor-binding SET domain proteins (NSD's), such as 6-amino-9H-purin-9-yl, imidazo[2,1-f][1,2,4]triazin-4-amine, 4-amino pyrazolo[1,5...
|
|
WO/2024/102927A1 |
The disclosure provides compounds, in part, compounds of Formula I, Formula II or Formula III and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical composit...
|
|
WO/2024/102997A1 |
The present invention discloses methods to prevent gout flares using IL-1β inhibitors. A method of treating gout patients using methotrexate, canakinumab, and pegloticase is described.
|
|
WO/2024/100250A1 |
In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the inventi...
|
|
WO/2024/101337A1 |
Provided in one embodiment is a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing a splicing abnormality that causes onset or advance of a disease. The present disclosure provides in one embodiment a compoun...
|
|
WO/2024/100682A1 |
The present invention relates to sustained release composition of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof with less sedation. The present invention also relates sustained release compositions of Hydroxyzine...
|
|
WO/2024/098127A1 |
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous sol...
|
|
WO/2024/099992A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4 and R5 are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/103023A2 |
Disclosed is a method of treating lupus using therapeutically effective amount of a selective 12-lipoxygenase inhibitor. In some embodiments, the 12-lipoxygenase inhibitor is N-(benzo[d]thiazol-2-yl)-4-[(2-hydroxy-3-methoxybenzyl)amino
]...
|
|
WO/2024/101808A1 |
The present invention provides a protrusion patch and a method for manufacturing same. The protrusion patch comprises: an adhesive layer; and multiple patterned protrusions spaced apart from each other and attached to one surface of the ...
|
|
WO/2024/100219A1 |
The present invention relates to an active ingredient consisting of the following molecules: acetic acid, butyric acid, lactic acid and propionic acid, and/or a salt and/or an ester and/or an anhydride of one or more of these molecules, ...
|
|
WO/2024/103050A1 |
Disclosed are exosomes comprising a Na+ taurocholate co-transporting polypeptide (NTCP) binding motif, such as HBV preSl peptide (PS IP). Disclosed are methods of making exosomes that have been engineered to express a heterologous bindin...
|
|
WO/2024/099440A1 |
A fused ring compound, a use thereof, and a pharmaceutical composition containing same. The compound has a strong inhibitory effect on BRM ATPase, and has a good application prospect in BRG1 gene mutation tumors.
|
|
WO/2024/098590A1 |
Provided is a preparation method for a Qingkailing preparation, comprising: taking radix isatidis and subjecting same to reflux extraction twice using a 64-69 wt% aqueous ethanol solution; combining the resulting extracts, refrigerating ...
|
|
WO/2024/100379A1 |
The present invention relates to an orally disintegrating tablet obtainable by a wet granulation method comprising atorvastatin or pharmaceutically acceptable salts thereof, at least a diluent, a disintegrant agent, a solubilizer, and a ...
|
